Intensity Therapeutics Inc Overview
Industry: Biotechnology
Sector: Healthcare
Read MoreMavefund brings filings, fundamentals, valuation, price history and news for Intensity Therapeutics Inc into one research view. The sections below show what strengthens or weakens the research case.
Score
Reported Results
What the company reported, with filing details kept small.
Quarterly result summary
Net loss was -$2.4M (from $3.3M). R&D expense was $1.2M.
Net loss
-$2.4M
from $3.3M
R&D expense
$1.2M
reported
G&A expense
$1.3M
reported
Cash
$10.2M
reported
What changed
- Net loss was -$2.4M (from $3.3M).
Guidance / outlook
The Company expects presentation of more detailed results for the seven (7) Cohort A patients at a future oncology conference.
Earnings release
Open filing
Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.
Other recent earnings materials
SEC filing
8-K
May 07, 2026
SEC filing
10-Q
May 07, 2026
SEC filing
8-K
Mar 27, 2026
Earnings release
Earnings release
Mar 27, 2026
SEC filing
10-K
Mar 27, 2026
SEC filing
8-K
Mar 05, 2026
SEC filing
8-K
Nov 06, 2025
SEC filing
10-Q
Nov 06, 2025
Earnings release
Earnings release
Nov 06, 2025
Earnings release
Earnings release
Aug 07, 2025
SEC filing
8-K
Aug 07, 2025
Prediction-grade evidence
Recent News
Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.
Prelude Therapeutics (PRLD) Upgraded to Buy: Here's Why
Headline from Yahoo Finance: Prelude Therapeutics (PRLD) Upgraded to Buy: Here's Why.
Intensity Therapeutics resumes patient dosing in Swiss trial
Headline from Investing.com: Intensity Therapeutics resumes patient dosing in Swiss trial.
Intensity Therapeutics, Inc. Restarts Patient Treatment in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 Study)
Headline from PR Newswire: Intensity Therapeutics, Inc. Restarts Patient Treatment in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 Study).
Earnings Per Share
Score 0.00/5
Intensity Therapeutics Inc earns a low score, as its Earnings Per Share (EPS) has not shown continuous growth over the last six years. Notable counterparts in the sector with high scores includes
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
In
Biotechnology industry
, Halozyme Therapeutics Inc
, Corcept Therapeutics Incorporated
, Exelixis Inc
are companies with high ratings.
Return on Equity
Score 4.06/5
Intensity Therapeutics Inc stands out with a superior score in the Return on Equity (ROE) section, surpassing the sector median value and showcasing its strong performance in this metric. The top companies in the same sector include
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
Metric chart temporarily unavailable.
Net Margin
Score 4.28/5
Intensity Therapeutics Inc
commands a high score, propelled by its net margin consistently outpacing the sector median value and exhibiting continuous growth in recent six years; noteworthy counterparts in the sector, boasting similarly high scores, include
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
Metric chart temporarily unavailable.
Leverage
Score 4.81/5
Intensity Therapeutics Inc
attains a commendable score in the category due to its lower leverage ratio over the past six years in comparison to the sector median value. Additionally, other notable companies in the same sector, such as
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
, also exhibit high scores.
0
1
2
3
4
Leverage
Company —
Sector Median —
0
1
2
3
4
Leverage
Company —
Sector Median —
0
1
2
3
4
Leverage
Company —
Sector Median —
0
1
2
3
4
Leverage
Company —
Sector Median —
Metric chart temporarily unavailable.
Financial Statements
Company-reported SEC EDGAR facts organized into the three core statements.
Verified SEC statements load when this section enters view.
Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.
Financial Ratio
Yearly
Quarterly
Financial
Profitability
Growth
Cash Flow
Financial Health
Efficiency Ratios